Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New S...(commitments to supportthe coordinating r...),Health

Date:10/11/2007

commitments to support the coordinating role of the secretariat. The US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), has awarded up to US$7 million over the next seven years, and the Bill & Melinda Gates Foundation has committed $20 million over the next four years to support the secretariat's activities.

"The enormous scientific obstacles in identifying an effective HIV vaccine combined with the urgent need for improved HIV prevention support the need for increased coordination and collaboration globally to accelerate progress," said Anthony S. Fauci, M.D., Director of NIAID. "Dr. Bernstein has a proven track record building a world-class scientific organization that brings together researchers, funders, advocates and industry. The Enterprise, under Dr. Bernstein's leadership, can bring new energy to the HIV vaccine field and help us work together in a coordinated manner to tackle these major obstacles as quickly as possible."

Dr. Bernstein was previously the founding president of the Canadian Institutes of Health Research. Over the past seven years, he has built CIHR into one of the world's leading research agencies, supporting more than 11,000 health researchers with an annual budget of US$1 billion.

"Alan Bernstein's appointment as executive director brings increased momentum to the Enterprise's essential efforts to help accelerate the search for an HIV vaccine," said Dr. Seth Berkley, President and CEO of the International AIDS Vaccine Initiative. "This is a wonderful opportunity for those of us working in the field to derive an added level of synergy by working together across all stages of HIV vaccine development."

"The Enterprise has an important role to play in ensuring that HIV vaccine development efforts match the magnitude of the pandemic. The 2005 Enterprise scientific plan charts a broad path forward - we must explore multiple approaches and aggressively pursu
'/>"/>

SOURCE The Global HIV Vaccine Enterprise Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
7. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
8. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
9. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma